logo-loader
BioPorto

BioPorto optimistic over FDA clearance for its NGAL kidney diagnostic test for use on children

BioPorto A/S (CPH:BIOPOR) CEO Peter Eriksen tells Proactive Investors the Denmark-based diagnostics company recently held a positive meeting with the FDA regarding its NGAL kidney diagnostic test for use on children.

Eriksen notes that the FDA requested additional information mid-July in order for the company to receive clearance for the test as an acute kidney injury diagnostic. The CEO says the firm is in talks with key children's hospitals around the US, and sees a 'clear path forward' for the test.

Quick facts: BioPorto

Price: £0.00

Market: NASDAQ OMX
Market Cap: £0.00
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioPorto named herein, including the promotion by the Company of BioPorto in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: BioPorto reveals 'healthy growth' in second quarter revenue

BioPorto A/S (CPH:BIOPOR) CFO Ole Larsen tells Proactive the diagnostic company saw "healthy growth" in revenue for the second quarter, where revenue grew by 10% to DKK (Danish Krone) 7.8 million (US$1.16 million) compared to DKK 7.2 million (US$1.08 million) in the same period in the previous...

on 08/15/2019

2 min read